57 related articles for article (PubMed ID: 38459598)
1. PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG.
Kramer-Marek G; Bernardo M; Kiesewetter DO; Bagci U; Kuban M; Aras O; Zielinski R; Seidel J; Choyke P; Capala J
J Nucl Med; 2012 Jun; 53(6):939-46. PubMed ID: 22582046
[TBL] [Abstract][Full Text] [Related]
2. Extra-striatal Uptake of
Chandra P; Nath S
Indian J Nucl Med; 2017; 32(3):243-244. PubMed ID: 28680218
[TBL] [Abstract][Full Text] [Related]
3. Fluoroquinolones as imaging agents for bacterial infection.
Naqvi SAR; Drlica K
Dalton Trans; 2017 Oct; 46(42):14452-14460. PubMed ID: 28920628
[TBL] [Abstract][Full Text] [Related]
4. Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer.
Wu J; Chen J; Zhao Y; Yuan M; Chen X; He X; Zhang J; Shao G; Sun Q
Mol Pharm; 2024 Jun; ():. PubMed ID: 38843446
[TBL] [Abstract][Full Text] [Related]
5. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives.
Li J; Gong C; Zhou H; Liu J; Xia X; Ha W; Jiang Y; Liu Q; Xiong H
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791529
[TBL] [Abstract][Full Text] [Related]
6. Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer.
Gao F; Liu F; Wang J; Bi J; Zhai L; Li D
J Cancer Res Clin Oncol; 2024 Mar; 150(3):118. PubMed ID: 38466436
[TBL] [Abstract][Full Text] [Related]
7. Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.
Henry KE; Ulaner GA; Lewis JS
PET Clin; 2018 Jul; 13(3):423-435. PubMed ID: 30100080
[TBL] [Abstract][Full Text] [Related]
8. Detection of HER2 expression using
Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Intra-individual comparison of
Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
[TBL] [Abstract][Full Text] [Related]
11. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer
Shi J; Du S; Wang R; Gao H; Luo Q; Hou G; Zhou Y; Zhu Z; Wang F
J Transl Med; 2023 Jan; 21(1):19. PubMed ID: 36631812
[TBL] [Abstract][Full Text] [Related]
14. High in-vivo stability in preclinical and first-in-human experiments with [
Qin X; Guo X; Liu T; Li L; Zhou N; Ma X; Meng X; Liu J; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):302-313. PubMed ID: 36129493
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
